1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,420 | 0,429 | 10:22 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.07. | Oncodesign Precision Medicine: OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position | 419 | Business Wire | The REVERT Phase 1b/2a clinical trial evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 has been submitted to the Swiss regulatory (Swissmedic) and ethics (Swiss ethics)... ► Artikel lesen | |
| 11.07. | Oncodesign Precision Medicine - Precision therapies for resistant diseases | 334 | Edison Investment Research | Oncodesign Precision Medicine (OPM) is a clinical-stage biopharmaceutical company listed on Euronext Growth Paris. OPM is developing precision medicine therapies targeting treatment-resistant and metastatic... ► Artikel lesen | |
| 17.04. | Oncodesign Precision Medicine Announces Equity Financing of up to 5 Million Euros | 315 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 03.04. | Oncodesign Precision Medicine: OPM Announces Its 2024 Annual Results and Clinical Developments | 322 | Business Wire | OPM-101: preclinical work establishing POC in immuno-oncology, end of phase 1 healthy volunteers and preparation for phase 1b/2a Reintegration of OPM-201 into OPM's portfolio of proprietary... ► Artikel lesen | |
| 24.03. | Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1 | 446 | Business Wire | OPM-101 will be evaluated in a Phase 1b/2a clinical trial, in combination with pembrolizumab, a monoclonal antibody directed against the PD-1 protein, in patients with advanced melanoma resistant... ► Artikel lesen | |
| ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
| 04.03. | Oncodesign Precision Medicine: Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors | 374 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 20.12.24 | Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers | 421 | Business Wire | Retrieval by OPM of all rights to the OPM-201 program and associated patent portfolio Confirmation of the molecule's safety in healthy volunteers
Regulatory News:
Oncodesign Precision... ► Artikel lesen | |
| 22.10.24 | Oncodesign Precision Medicine: OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a | 426 | Business Wire | Finalization of the study report on the double-blind, placebo-controlled Phase 1 trial of OPM-101 in 104 healthy volunteers (HV) who received OPM-101 24-hour ECG analysis reveals no toxic... ► Artikel lesen | |
| 15.10.24 | Oncodesign Precision Medicine: OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference | 357 | Business Wire | Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM Clinical Development) of safety, pharmacokinetic... ► Artikel lesen | |
| 25.09.24 | Oncodesign Precision Medicine: OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation | 468 | Business Wire | OPM-101 successfully completed its Phase 1 trial with healthy volunteers, enabling the company to anticipate the start of a Phase 1b/2a clinical trial in 2024/early 2025. OPM-201, licensed... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics prices upsized $250M stock offering | ||
| AVIDITY BIOSCIENCES | 47,230 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 40,690 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update | Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,200 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARCELLX | 69,75 | 0,00 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial | ||
| TARSUS PHARMACEUTICALS | 58,59 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,840 | 0,00 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
| TREVI THERAPEUTICS | 7,270 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| NUVALENT | 76,90 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 44,940 | -1,32 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| UPSTREAM BIO | 20,260 | 0,00 % | Upstream Bio, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,660 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| CG ONCOLOGY | 27,460 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates | - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,310 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| DYNE THERAPEUTICS | 13,500 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen |
ONCODESIGN PRECISION MEDICINE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,399 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCODESIGN PRECISION MEDICINE SA finden Sie auf Wallstreet Online.